Meizhen Zhong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Meizhen Zhong has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Baicheng Deng
Department of Parasitology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510080, China
1 shared publication - Huaiqiu Huang
Department of Dermatology and Venereology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
1 shared publication - Ling Hu
Department of Dermatology and Venereology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510600, China
1 shared publication - Xiaoyu Zhi
Department of Dermatology and Venereology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510600, China
1 shared publication - Xuchu Hu
Department of Parasitology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
1 shared publication - Yuyan Hong
Department of Dermatology and Venereology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510600, China
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (9) , 706
SgtrCypB Formulated with Freund’s Adjuvant Confers Protective Immunity Against S. globosa and Partial Cross-Protection Against S. schenckii Infections in Mice
Sporothrix globosa is the predominant cause of sporotrichosis in China, highlighting the need for effective vaccine strategies. Cyclophilins from pathogenic microorganisms have emerged as potential vaccine antigens. We previously generated a high-yield, high-purity recombinant truncated S. globosa cyclophilin B protein (SgtrCypB) retaining its functional domain. Here, BALB/c mice were immunized subcutaneously with SgtrCypB alone or formulated with Freund’s adjuvant to evaluate immunogenicity. Only the adjuvant-formulated vaccine induced a high antibody titer (1:51,200). Then, the infection-challenge experiments compared the SgtrCypB formulated with Freund’s adjuvant and PBS formulated with Freund’s adjuvant groups. Following challenge, SgtrCypB plus adjuvant reduced cutaneous lesion size (0.6 vs. 1.0 cm at week 1) without significantly affecting ulcer incidence. In systemic S. globosa infection, vaccination increased survival to 90% versus 40% in controls and reduced organ fungal burdens. Partial cross-protection was observed against S. schenckii, with 60% versus 20% survival and lower fungal burdens in the kidneys and lungs. Protection against C. albicans was minimal. These findings identify SgtrCypB as a promising protective antigen against S. globosa and S. schenckii and support further evaluation with clinically applicable adjuvants.
- 21 September 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (9) , 706
Open AccessSgtrCypB Formulated with Freund’s Adjuvant Confers Protective Immunity Against S. globosa and Partial Cross-Protection Against S. schenckii Infections in Mice
Sporothrix globosa is the predominant cause of sporotrichosis in China, highlighting the need for effective vaccine strategies. Cyclophilins from pathogenic microorganisms have emerged as potential vaccine antigens. We previously generated a high-yield, high-purity recombinant truncated S. globosa cyclophilin B protein (SgtrCypB) retaining its functional domain. Here, BALB/c mice were immunized subcutaneously with SgtrCypB alone or formulated with Freund’s adjuvant to evaluate immunogenicity. Only the adjuvant-formulated vaccine induced a high antibody titer (1:51,200). Then, the infection-challenge experiments compared the SgtrCypB formulated with Freund’s adjuvant and PBS formulated with Freund’s adjuvant groups. Following challenge, SgtrCypB plus adjuvant reduced cutaneous lesion size (0.6 vs. 1.0 cm at week 1) without significantly affecting ulcer incidence. In systemic S. globosa infection, vaccination increased survival to 90% versus 40% in controls and reduced organ fungal burdens. Partial cross-protection was observed against S. schenckii, with 60% versus 20% survival and lower fungal burdens in the kidneys and lungs. Protection against C. albicans was minimal. These findings identify SgtrCypB as a promising protective antigen against S. globosa and S. schenckii and support further evaluation with clinically applicable adjuvants.